The U.S. Preventive Services Task Force released draft guidelines urging providers to discuss with their female patients the benefits and dangers of drugs that could reduce breast cancer risks. Providers should offer tamoxifen or raloxifene in cases of increased risk of breast cancer and when side effects appear unlikely. A research analysis performed by USPSTF and reported in the Annals of Internal Medicine found that tamoxifen and raloxifene reduced women's breast cancer risk by up to 56%.

Full Story:
Reuters, DailyRx.com

Related Summaries